This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Preston, S. L.
Right arrow Articles by Corrado, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Preston, S. L.
Right arrow Articles by Corrado, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1998, p. 1098-1104, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired Infection

Sandra L. Preston,1,2 George L. Drusano,1,* Adam L. Berman,1 Cynthia L. Fowler,3 Andrew T. Chow,3 Bruce Dornseif,3 Veronica Reichl,3 Jaya Natarajan,3 Frankie A. Wong,3 and Michael Corrado3

Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Albany Medical College,1 Department of Pharmacy Practice, Albany College of Pharmacy,2 Albany, New York, and Robert Wood Johnson Pharmaceutical Research Institute, Raritan New Jersey3

Received 8 July 1997/Returned for modification 31 December 1997/Accepted 10 February 1998

Population pharmacokinetic modeling is a useful approach to obtaining estimates of both population and individual pharmacokinetic parameter values. The potential for relating pharmacokinetic parameters to pharmacodynamic outcome variables, such as efficacy and toxicity, exists. A logistic regression relationship between the probability of a successful clinical and microbiological outcome and the peak concentration-to-MIC ratio (and also the area under the plasma concentration-time curve [AUC]/MIC ratio) has previously been developed for levofloxacin; however, levofloxacin assays for determination of the concentration in plasma are not readily available. We attempted to derive and validate demographic variable models to allow prediction of the peak concentration in plasma and clearance (CL) from plasma for levofloxacin. Two hundred seventy-two patients received levofloxacin intravenously for the treatment of community-acquired infection of the respiratory tract, skin or soft tissue, or urinary tract, and concentrations in plasma, guided by optimal sampling theory, were obtained. Patient data were analyzed by the Non-Parametric Expectation Maximization approach. Maximum a posteriori probability Bayesian estimation was used to generate individual parameter values, including CL. Peak concentrations were simulated from these estimates. The first 172 patients were used to produce demographic models for the prediction of CL and the peak concentration. The remaining 100 patients served as the validation group for the model. A median bias and median precision were calculated. A two-compartment model was used for the population pharmacokinetic analysis. The mean CL and the mean volume of distribution of the central compartment (V1) were 9.27 liters/h and 0.836 liter/kg, respectively. The mean values for the intercompartmental rate constants, the rate constant from the central compartment to the peripheral compartment (Kcp) and the rate constant from the peripheral compartment to the central compartment (Kpc), were 0.487 and 0.647 h-1, respectively. The mean peak concentration and the mean AUC values normalized to a dosage of 500 mg every 24 h were 8.67 µg/ml and 72.53 µg · h/ml, respectively. The variables included in the final model for the prediction of CL were creatinine clearance (CLCR), race, and age. The median bias and median precision were 0.5 and 18.3%, respectively. Peak concentrations were predicted by using the demographic model-predicted parameters of CL, V1, Kcp, and Kpc, in the simulation. The median bias and the median precision were 3.3 and 21.8%, respectively. A population model of the disposition of levofloxacin has been developed. Population demographic models for the prediction of peak concentration and CL from plasma have also been successfully developed. However, the performance of the model for the prediction of peak concentration was likely insufficient to be of adequate clinical utility. The model for the prediction of CL was relatively robust, with acceptable bias and precision, and explained a reasonable amount of the variance in the CL of levofloxacin from plasma in the population (r2 = 0.396). Estimated CLCR, age, and race were the final model covariates, with CLCR explaining most of the population variance in the CL of levofloxacin from plasma. This model can potentially optimize the benefit derived from the pharmacodynamic relationships previously developed for levofloxacin.

* Corresponding author. Mailing address: Division of Clinical Pharmacology, Departments of Medicine and Pharmacology A-142, Albany Medical College, 47 New Scotland Ave., Albany, NY 12208. Phone: (518) 262-6330. Fax: (518) 263-6333. E-mail: GLDRUSANO{at}AOL.COM.

Antimicrobial Agents and Chemotherapy, May 1998, p. 1098-1104, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Dupont, P., Hocquet, D., Jeannot, K., Chavanet, P., Plesiat, P. (2005). Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. J Antimicrob Chemother 55: 518-522 [Abstract] [Full Text]  
  • Lodise, T. P. Jr., Lomaestro, B., Rodvold, K. A., Danziger, L. H., Drusano, G. L. (2004). Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation. Antimicrob. Agents Chemother. 48: 4718-4724 [Abstract] [Full Text]  
  • Smith, H. J., Noreddin, A. M., Siemens, C. G., Schurek, K. N., Greisman, J., Hoban, C. J., Hoban, D. J., Zhanel, G. G. (2004). Designing Fluoroquinolone Breakpoints for Streptococcus pneumoniae by Using Genetics instead of Pharmacokinetics-Pharmacodynamics. Antimicrob. Agents Chemother. 48: 3630-3635 [Abstract] [Full Text]  
  • Preston, S. L (2004). The Importance of Appropriate Antimicrobial Dosing: Pharmacokinetic and Pharmacodynamic Considerations. The Annals of Pharmacotherapy 38: S14-S18 [Abstract] [Full Text]  
  • Pea, F., Pavan, F., Nascimben, E., Benetton, C., Scotton, P. G., Vaglia, A., Furlanut, M. (2003). Levofloxacin Disposition in Cerebrospinal Fluid in Patients with External Ventriculostomy. Antimicrob. Agents Chemother. 47: 3104-3108 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials. The Annals of Pharmacotherapy 37: 1478-1488 [Abstract] [Full Text]  
  • Tam, V. H., Preston, S. L., Drusano, G. L. (2003). Optimal Sampling Schedule Design for Populations of Patients. Antimicrob. Agents Chemother. 47: 2888-2891 [Abstract] [Full Text]  
  • Rodvold, K. A., Danziger, L. H., Gotfried, M. H. (2003). Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults. Antimicrob. Agents Chemother. 47: 2450-2457 [Abstract] [Full Text]  
  • Jones, R. N., Rubino, C. M., Bhavnani, S. M., Ambrose, P. G. (2003). Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother. 47: 292-296 [Abstract] [Full Text]  
  • Furlanut, M., Brollo, L., Lugatti, E., Di Qual, E., Dolcet, F., Talmassons, G., Pea, F. (2003). Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 51: 101-106 [Abstract] [Full Text]  
  • Lode, H., Allewelt, M. (2002). Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother 50: 151-154 [Full Text]  
  • Lode, H., Allewelt, M. (2002). Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother 49: 709-712 [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Schrenzel, J., Lew, D. P. (2002). Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 1503-1509 [Abstract] [Full Text]  
  • (2001). BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 56: iv1-64 [Full Text]  
  • Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., Pierce, P. F. (2001). Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections. Antimicrob. Agents Chemother. 45: 2793-2797 [Abstract] [Full Text]  
  • Drusano, G. L., Preston, S. L., Van Guilder, M., North, D., Gombert, M., Oefelein, M., Boccumini, L., Weisinger, B., Corrado, M., Kahn, J. (2000). A Population Pharmacokinetic Analysis of the Penetration of the Prostate by Levofloxacin. Antimicrob. Agents Chemother. 44: 2046-2051 [Abstract] [Full Text]  
  • Trampuz, A., Wenk, M., Rajacic, Z., Zimmerli, W. (2000). Pharmacokinetics and Pharmacodynamics of Levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in Human Skin Blister Fluid. Antimicrob. Agents Chemother. 44: 1352-1355 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»